Dr. Stein on Commercial Tests to Determine Therapies for Prostate Cancer

Video

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses commercial tests for determining therapies for patients with prostate cancer.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses commercial tests for determining therapies for patients with prostate cancer.

Certain tests are helpful when understanding some of the more challenging clinical situations, explains Stein. It is not something that is routinely done, due to different insurance funds. However, it is effective during certain cases, in regards to determining which therapy a patient should receive.

Technology and platforms are developing quickly, making it necessary for physicians to remain updated on the ongoing trials in order to decide the most beneficial treatment for a patient. For instance, explains Stein, there might be trials looking at a particular biomarker, which could be an important way to determine which trials to enroll patients on.

Related Videos
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD